Summit Therapeutics Income Statement (2018-2026) | SMMT

Income Statement Jan2018 Jan2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.06M1.31M0.25M0.25M0.23M0.22M
Operating items
Research & Development (Quarter)
23.92M19.94M23.11M20.56M9.01M17.05M5.39M9.88M9.45M15.32M24.81M30.87M30.80M37.72M51.38M51.27M208.02M131.10M147.29M132.62M
Selling, General & Administrative (Quarter)
5.98M5.66M7.78M6.66M6.93M5.57M7.58M6.94M6.32M5.43M10.57M11.52M13.81M20.65M14.23M15.59M360.42M103.11M77.63M62.59M
Other Operating Expenses (Quarter)
3.01M5.46M1.13M0.58M-0.03M0.27M0.18M0.21M0.16M-0.26M0.20M
Operating Expenses (Quarter)
29.91M25.61M30.89M27.21M15.94M22.62M21.43M537.74M15.77M20.76M35.39M42.39M59.62M58.38M65.61M66.85M568.44M234.21M224.93M195.21M
Operating Income (Quarter)
-23.73M-19.49M-26.05M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-42.39M-59.62M-58.38M-65.61M
EBIT (Quarter)
-23.73M-19.49M-26.05M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-42.39M-59.62M-58.38M-65.61M
Non-operating items
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)
-0.69M-0.11M-1.05M0.76M-4.08M-4.45M5.47M-5.22M1.08M-0.78M16.10M2.04M2.33M4.58M4.42M3.94M2.73M2.42M5.75M5.79M
Net income details
EBT (Quarter)
-24.42M-19.60M-27.10M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-45.51M-62.72M-60.83M-65.62M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-24.42M-19.60M-27.10M-21.40M-16.77M-21.39M-19.23M-542.38M-14.72M-21.27M-36.57M-43.47M-60.38M-56.25M-61.20M-62.91M-565.71M-231.79M-219.17M-189.42M
Income from Continuing Operations (Quarter)
-24.42M-19.60M-27.10M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-45.51M-62.72M-60.83M-65.62M
Consolidated Net Income (Quarter)
-24.42M-19.60M-27.10M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-45.51M-62.72M-60.83M-65.62M
Income towards Parent Company (Quarter)
-24.42M-19.60M-27.10M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-45.51M-62.72M-60.83M-65.62M
Net Income towards Common Stockholders (Quarter)
-24.42M-19.60M-27.10M-22.16M-12.69M-16.94M-20.30M-537.15M-15.79M-20.49M-36.21M-45.51M-62.72M-60.83M-65.62M
Additional items
EPS (Basic) (Quarter)
-0.27-0.20-0.21-0.15-0.12-0.10-0.04-1.43-0.02-0.03-0.01-0.06-0.09-0.08-0.09-0.09-0.76-0.31-0.28-0.24
EPS (Weighted Average and Diluted) (Quarter)
-0.27-0.20-0.21-0.15-0.12-0.10-0.04-1.43-0.02-0.03-0.01-0.06-0.09-0.08-0.09-0.09-0.76-0.31-0.28-0.24
Shares Outstanding (Weighted Average) (Quarter)
92.07M98.97M131.71M140.04M140.08M208.91M193.34M378.16M697.69M697.74M619.65M701.79M704.84M726.66M718.54M738.08M740.36M741.39M775.46M
Shares Outstanding (Diluted Average) (Quarter)
92.07M98.97M131.71M140.04M140.08M208.91M193.34M378.16M538.81M697.74M619.65M701.79M704.84M712.17M718.54M738.08M740.36M743.42M747.70M775.46M
EBITDA (Quarter)
-23.88M-20.46M-25.85M-23.16M-15.98M-21.43M-17.91M-541.88M-15.76M-21.15M-36.69M-43.47M-60.34M-56.06M-61.18M-63.19M-565.90M-231.75M-219.00M-189.52M
Interest Expenses (Quarter)
3.12M3.10M2.45M0.01M
Tax Rate (Quarter)